Lung Cancer

The FDA has approved the Oncomine Dx Target Test to identify patients with HER2-mutant non-small cell lung cancer who are eligible for Hernexeos treatment.

Beginning treatment for your lung cancer often brings questions surrounding what side effects will be experienced, according to Dr. Jacob Sands.

Clara Cirks is a stage 4 lung cancer patient who uses platforms like TikTok and Instagram to amplify her voice and raise awareness about patient advocacy

The FDA approved Hernexeos for adults with unresectable or metastatic non-squamous non-small cell lung cancer.

In an interview with CURE, Clara Cirks shares the emotional weight of finishing chemo while facing ongoing immunotherapy and the uncertainty it brings.

Following the June 2025 FDA approval of Datroway, Dr. Jacob A. Sands explained the significance of the regulatory approval for patients with lung cancer.

Dr. Jacob A. Sands shares how antibody-drug conjugates, such as Datroway, work to selectively target and destroy tumor cells among those with lung cancer.

After joining a creative survivors’ group, I discovered that emotional expression, art and connection offered a profound kind of healing beyond treatment.

In July of 2025, the U.S. Food and Drug Administration approved various anti-cancer treatments and therapeutic approaches across a range of disease types.

LiveLung invites the Wilmington community to its monthly educational meeting.

The August LiveLung Virtual meeting will feature Nitin Ohri, MD, MS, Board Certified Radiation Oncologist and Professor of Radiation Oncology at Montefiore Einstein.

LiveLung invites the Triad lung cancer community to its monthly educational meeting.

Robotic and video-assisted thoracic surgery reduces recovery time for those with lung cancer, allowing some to leave the hospital the day after surgery.

CURE spoke with a thoracic surgeon about the impact of minimally invasive surgery for patients.

Dr. Jacob Sands discusses the significance of the FDA approval of Datroway for the treatment of patients with locally advanced or metastatic EGFR+ NSCLC.

As July concludes, momentum in lung cancer research continues to build, marked by FDA decisions, trial progress, and patient-centered perspectives.

The FDA awarded orphan drug designation to VT3989 for mesothelioma, supporting the experimental cancer treatment’s development.

Dr. Jacob Sands discusses progress in lung cancer treatment, as well as what patients should understand about how their care options may evolve over time.

Self-compassion, emotional openness, and community support is incredibly important for patients currently beginning their cancer journey.

New clinical trials are advancing treatments for cutaneous T-cell lymphoma, advanced solid tumors, pediatric sarcomas and ALK-positive lung cancer.

The FDA granted fast track status to DB-1310, a HER3-targeting antibody-drug conjugate, for advanced nonsquamous non-small cell lung cancer.

Tagrisso with chemo significantly improved survival and progression-free outcomes versus Tagrisso alone in newly diagnosed advanced EGFR-mutated lung cancer.

The absence of tobacco use suggests alternative carcinogenic mechanisms may contribute to lung cancer development in younger individuals.

Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt.